Novel MicroNet-Covered Stent Sets New Safety Standard for High-Risk Carotid Artery Stenting: Insights from the C-GUARDIANS Trial

Highlights

• The C-GUARDIANS trial demonstrates a primary endpoint (30-day DSMI and 1-year ipsilateral stroke) incidence of only 1.93%.
• The 30-day rate of death, stroke, or myocardial infarction (DSMI) was 0.95%, representing a significant safety profile in high-risk patients.
• The MicroNet-covered stent technology effectively addresses the embolic window by preventing plaque protrusion through the stent struts.
• Target lesion revascularization (TLR) at one year remained exceptionally low at 1.0%.

The Evolution of Carotid Artery Stenting and the Persistent Embolic Challenge